Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 24946

Original article / research
Table of Contents - Year : 2016 | Month : April | Volume : 10 | Issue : 4 | Page : FF01 - FF05

Effect of Silybin on Lipid Profile in Hypercholesterolaemic Rats FF01-FF05

Senthil Gobalakrishnan, Sylvia Santhakumari Asirvatham, Venkatraman Janarthanam

Dr. Senthil Gobalakrishnan,
Assistant Professor, Department of Pharmacology, Sri Manakula Vinayagar Medical College, Pondicherry-605107, India.

Introduction: Hyperlipidemia is a major cause of atherosclerosis and atherosclerosis associated conditions, such as Coronary Heart Disease (CHD), ischaemic cerebrovascular disease and peripheral vascular disease. Though there are hypolipidemic drugs available, the search for a more efficacious hypo lipidemic agent was always going on.

Aim: To study the effect of Silybin on lipid profile in Hypercholesterolaemic rats.

Materials and Methods: After grant of permission from animal ethics committee, the animals were divided into four groups of eight each (normal control, Experimental control with High cholesterol diet, High cholesterol diet + Silybin 300mg, High cholesterol diet + Silybin 600mg). At the end of 60 days the animals in all the groups were subjected to overnight fasting followed by plasma and liver biochemical analyses.

Statistical Analysis: The data were analysed by ANNOVA followed by Duncan’s multi range test and the value of p=0.05 was used as the criterion for statistical significance.

Results: The rats fed on high cholesterol diet showed significant increase in serum total cholesterol, Triglycerides, LDL-C and VLDL-C. Treatment with Silybin significantly decreased serum total cholesterol (24%), Triglycerides (21%), LDL-C (24%) in a dose dependent manner. Rats treated with Silybin (300 and 600 mg/kg) showed significant increase in hepatic HDL –C and decrease in other lipid profiles.

Conclusion: Treatment with Silybin significantly decreased both serum and hepatic total cholesterol, triglycerides, VLDL-C, LDL-C and increased HDL-C at both doses.